FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Supplemental Application (Neos Therapeutics, LP)

View source ↗

Summary

FDA approved a supplemental application for Amphetamine Extended-Release by Neos Therapeutics, LP under NDA 204326.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• AMPHETAMINE EXTENDED-RELEASE (Amphetamine extended-release)

Snippet

SUPPL AP for AMPHETAMINE EXTENDED-RELEASE (AMPHETAMINE EXTENDED-RELEASE)